Heparin as a Therapy for Atherosclerosis: Preliminary Observations on the Intrapulmonary Administration of Low-Dose Heparin in the Morning Versus Evening Gauged by Its Effect on Blood Variables

References

• Engelberg H. Heparin and the prevention of atherosclerosis. Basic research and clinical application. Wiley-Liss Division, New York 1990
   Google Scholar
• Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson G K. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985; 76: 125–31
   PubMed Web of Science ®Google Scholar
• Cerilli J, Brasile L, Karmody A. Role of the vascular endothelial cell antigen system in the etiology of atherosclerosis. Ann Surg 1985; 202: 329–34
   Google Scholar
• Hansson G K, Holm J, Krai J G. Accumulation of IgG and complement factor C3 in human arterial endothelium and atherosclerotic lesions. Acta Pathol Microbiol Immunol Scand 1984; 92: 429–35
   Google Scholar
• Vlaicu R E, Rus H G, Niculescu F, Cristea A. Immunoglobulins and complement components in human aortic atherosclerotic intima. Atherosclerosis 1985; 55: 35–50
   Google Scholar
• Schwartz C J, Mitchell J RA. Cellular infiltration of the human arterial adventitia associated with atheromatous plaques. Circulation 1962; 26: 73–8
   Google Scholar
• Nelson D S. The effects of anticoagulants and other drugs on cellular and cutaneous reactions to antigen in guinea-pigs with delayed-type hypersensitivity. Immunology 1965; 9: 219–34
   PubMed Web of Science ®Google Scholar
• Taylor H E, Culling C FA. Cytopathic effect of sensitized spleen cells on fibroblasts. The protective effect of heparin. Lab Invest 1966; 15: 1960–5
   Google Scholar
• Chelmicka-Szorc E, Arnason G W. Partial suppression of experimental allergic encephalomyelitis with heparin. Arch Neurol 1972; 27: 153–8
   Google Scholar
• Martz E, Benacerraf B. Inhibition of immune cell-mediated killing by heparin. Clin Immunol Immu-nopathol 1973; 1: 533–46
   Google Scholar
• McMillan R. Heparin in delayed transplant function. Lancet 1968; 1: 1178–80
   Google Scholar
• MacDonald A, Busch G J, Alexander J L, Pheteplace E A, Menzoian J, Murray J E. Heparin and aspirin in the treatment of hyperacute rejection of renal allografts in presensitized dogs. Transplantation 1970; 9: 1–7
   Google Scholar
• Bailie Y, Blanc T, Monties J-R, Goudard A, Jausseran T M, Henry E. Organ transplantation under heparin: an experimental and clinical study of a two-year experience. Coagulation problems in transplanted organs, K N von Kaulla. Charles C Thomas, Springfield, IL 1972; 166–78
   Google Scholar
• Colman R W, Girey G, Galvanek E G, Busch G J. Human renal allografts: the protective effects of heparin, kallikrein activation, and fibrinolysis during hyperacute rejection. Coagulation problems in transplanted organs, K N von Kaulla. Charles C Thomas, Springfield, IL 1972; 87–106
   Google Scholar
• Lider O, Baharav E, Mekori Y A, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83: 752–6
   PubMed Web of Science ®Google Scholar
• Lagodzinski Z, Gorski A, Wasik M. Immunosuppressive action of low-dose heparin. Effect on skin allograft survival. Transplantation 1990; 50: 714–5
   Google Scholar
• Engelberg H, Kuhn R, Steinman M. A controlled study of the effect of intermittent heparin therapy on the course of human coronary atherosclerosis. Circulation 1956; 13: 489–506
   Google Scholar
• Hughes M L, Mortenson F, Shourie L. Comparison of continuous long-term heparin and oral anticoagulant therapy in patients with severe angina pectoris. Am Heart J 1965; 65: 615–27
   Google Scholar
• Engelberg H, Kuhn R. Further observations of long-term intermittent heparin therapy in human coronary atherosclerosis. Anticoagulant therapy in ischemic heart disease, E S Nichol. Grune & Stratton, New York 1965; 212–20
   Google Scholar
• Griffith G C, Boggs R P. Long-term heparin therapy for ischemic heart disease. Anticoagulant therapy in ischemic heart disease, E S Nichol. Grune & Stratton, New York 1965; 134–7
   Google Scholar
• Wagner R T. Long term heparin therapy in ischemic heart disease. Anticoagulant therapy in ischemic heart disease, E S Nichol. Grune & Stratton, New York 1965; 284–9
   Google Scholar
• Carlson L A, Bottiger L E, Engstedt L, Oro L. Long-term heparin treatment in ischemic heart disease. Effects on clinical condition and plasma lipids. Acta Med Scand 1967; 182: 245–57
   Google Scholar
• Gertler M M, Leetma H E, Koutrouby R J, Johnson E D. Long-term use of minidose heparin in post-myocardial infarction. Adv Exp Med Biol 1975; 52: 341–50
   Google Scholar
• Gertler M M, Leetma H E, Guthrie R, Yablon M. Long term use of heparin in post myocardial infarction and angina pectoris. Chemistry and biology of heparin, R L Lundblod, W V Brown, K G Mann, H R Roberts. Elsevier/North-Holland, New York 1981; 571–80
   Google Scholar
• Sayen J J, Singer R B, Pierce G, Horwitz O. Unstable angina, myocardial infarction, heparin and death. Medium dose heparin in treatment of patients with acute coronary event. First year and long-term comparative mortality. Trans Am Clin Climatol Assoc 1982; 94: 141–53
   Google Scholar
• Ruggiero H A, Previde O, Califano S E, Beilis P, Val A. Medical treatment of threat syndrome with heparin. A long-term prospective study. Ann Cardiol Angeiol (Paris) 1983; 32: 181–6
   Google Scholar
• Neri Serneri G G, Rovelli F, Gensini G F, Purelli S, Carnovalli M, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987; 1: 937–42
   PubMed Web of Science ®Google Scholar
• Molino N, Belluardo C. Consideration on the long term use of heparin in cardiovascular subjects. A new method of administration: via aerosol. Min Cardioangiol 1973; 22: 553–7
   Google Scholar
• Yusuf S, Collins R, MacMahon S, Peto R. Effect of I.V. nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet 1988; 1: 1088–92
   PubMed Web of Science ®Google Scholar
• Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. JAMA 1988; 260: 2088–93
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration: secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–31
   PubMed Web of Science ®Google Scholar
• Brensike J F, Levy R I, Kelsey S F, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313–24
   PubMed Web of Science ®Google Scholar
• Blankenhorn D H, Nessim S A, Johnson R L, Sanmaro M E, Azen S P, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233–40
   PubMed Web of Science ®Google Scholar
• Canner P L, Berge K G, Wenger N K, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo M O, Frick M H, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260: 641–51
   PubMed Web of Science ®Google Scholar
• Brown G, Albers J J, Fisher L D, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–98
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rehabilitation and comprehensive secondary prevention after acute myocardial infarction. Euro Rep Study 1983; 84: 1–99
   Google Scholar
• O'Connor G T, Buring J E, Yusuf S, Goldhaber S, Olmstead E M, Paffenbarger R S, Hennekens C H. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234–44
   PubMed Web of Science ®Google Scholar
• Griffith G C, Nichols G, Asher J D. Heparin osteoporosis. JAMA 1965; 193: 85–8, Chronobiol Int. Vol. 8. No. 3, 1991
   Web of Science ®Google Scholar
• Avioli L V. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol 1975; 52: 375–84
   PubMedGoogle Scholar
• Phillips M Y, Copley J B, Stor R A. Thrombocytopenia and low dose heparin. Southern Med J 1983; 76: 526–8
   Google Scholar
• King D J, Kelton J G. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535–40
   PubMed Web of Science ®Google Scholar
• Ansell J E, Price J M, Shak S, Beckner R R. Heparin-induced thrombocytopenia: what is its real frequency?. Chest 1985; 88: 878–82
   Google Scholar
• Kakkasseril J S, Oranley J J, Panke T, Grannan K. Heparin-induced thrombocytopenia: a prospective study of 142 patients. J Vase Surg 1985; 2: 382–4
   PubMed Web of Science ®Google Scholar
• Powers P J, Kelton J G, Carter C J. Studies on the frequency of heparin-associated thrombocytopenia. ThrombRes 1984; 33: 439–43
   PubMed Web of Science ®Google Scholar
• Green D. Heparin-induced thrombocytopenia. MedJAust 1986; 144(suppl)37–9
   Google Scholar
• Chong B H. Heparin-induced thrombocytopenia. Blood Rev 1988; 2: 108–14
   PubMed Web of Science ®Google Scholar
• Kelton J G, Sheridan E, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925–30
   PubMed Web of Science ®Google Scholar
• Jorpes J E. Heparin in the treatment of thrombosis, second edition. Oxford University Press, New York 1946
   Google Scholar
• Stanton P E, Jr., Evans J R, Lefemine A A, et al. White clot syndrome. Southern Med J 1988; 81: 616–20
   PubMed Web of Science ®Google Scholar
• Atkinson J L, Sundt T M, Jr., Kazmier F J, Bowie E JW, Whisnant J P. Heparin-induced thrombocytopenia and thrombosis in ischemic stroke. Mayo Clinic Proc 1988; 63: 353–61
   Google Scholar
• Rosner S W. Heparin administered as an aerosol. Vase Dis 1965; 2: 131–4
   Google Scholar
• Youngchaiyud P, Kettel L J, Cugell D W. The effect of heparin aerosol on airway conductance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1969; 99: 449–52
   Google Scholar
• Jacques L B, Mahadoo J, Kavanagh L W. Intrapulmonary heparin. A new procedure for anticoagulant therapy. Lancet 1976; 2: 1157–61
   Google Scholar
• Hellgren M, Hagnevik K, Blomback M. Heparin aerosol effect on blood coagulation and pulmonary function. ThrombRes 1981; 21: 493–502
   Google Scholar
• Bick R L, Ross E S. Clinical use of intrapulmonary heparin. Semin Thromb Hemost 1985; 77: 213–7
   Google Scholar
• Kazmier F J. Monitoring of heparin therapy. Chemistry and biology of heparin, R L Lundblod, W V Brown, K G Mann, H R Roberts. Elsevier/North-Holland, New York 1981; 615–23
   Google Scholar
• Kanabrocki E L, Sothern R B, Olwin J H, . Intrapulmonary administration of heparin in the morning and its effect upon blood variables. Annual reviews in chronopharmacology, A Reinberg, M Smolensky, G Labrecque, et al. Pergamon Press, New York 1990; Vol. 7: 169–72
   Google Scholar
• Winters C J, Sallman A L, Baker B J, Meadows J, Rico D M, Vesely D L. The N-terminus and a 4000 molecular weight peptide from the midportion of the N-terminus of the atrial natriuretic prohormone each circulate in man and increase in congestive heart failure. Circulation 1989; 80: 438–49
   PubMed Web of Science ®Google Scholar
• Jacques L B, Napke E, Levy S W. The metachromatic activity of urine following the injection of heparin. Cire Res 1953; 1: 321–30
   Google Scholar
• Nelson W, Tong Y L, Lee J K, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6: 305–23
   PubMedGoogle Scholar
• Bingham C, Arbogast B, Guillaume G C, Lee J K, Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 1982; 9: 397–439
   PubMedGoogle Scholar
• Mahadoo J, Hiebert L M, Wright C J, Jacques L B. Vascular distribution of intratracheally administered heparin. Ann NY Acad Sci 1981; 370: 650–61
   Google Scholar
• Decousus H A, Croze M, Levi F A, et al. Orcadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med J 1985; 290: 341–4
   PubMed Web of Science ®Google Scholar
• Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J. Circadian variations in blood coagulation parameters, alpha-antitrypsine antigen and platelet aggregation and retention in clinically-healthy subjects. Chronobiol Int 1990; 7: 203–16
   PubMed Web of Science ®Google Scholar
• Kannel W B, Wolf P A, Castelli W P, D'Agostino R B. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183–6
   PubMed Web of Science ®Google Scholar
• Handa K, Kono S, Saku K, et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209–13
   PubMed Web of Science ®Google Scholar
• Rayssiguier Y. Role of magnesium and potassium in the pathogenesis of arteriosclerosis. Magnesium 1984; 3: 226–38
   PubMedGoogle Scholar
• Altuth B M. Ischemic heart disease and magnesium. Magnesium 1988; 7: 57–67
   Google Scholar
• Bush E H, Ventura H O, Lavie C J. Heparin-induced hyperkalemia. Southern Med J 1987; 80: 1450–1
   Google Scholar
• Vergrat R, Manning E Z, Fabre J. Measure de la secretian de 1'aldosterone sous-administration d'um adrenostratique semi-syn Detique l'hepamhoids rol-8307. Rev Franc Etud Clin Biol 1963; 8: 667–72
   Google Scholar